In vitro cytotoxicity and anticancer effects of citral nanostructured lipid carrier on MDA MBA-231 human breast cancer cells

Nordin, Noraini; Yeap, Swee Keong; Rahman, Heshu Sulaiman; Zamberi, Nur Rizi; Abu, Nadiah; Mohamad, Nurul Elyani; How, Chee Wun; Masarudin, Mas Jaffri; Abdullah, Rasedee; Alitheen, Noorjahan Banu

doi:10.1038/s41598-018-38214-x

Cited by 79 publications

(46 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study, the potential anti-tumor effect of NLC-Citral was ascertained using MDA-MB-231 cells in vitro [12]. In this study, the oral efficacy of NLC-Citral as compared to the citral in suppressing the breast tumor growth was tested in 4T1-challenged mice treated for 28 days.…”

Section: Discussionmentioning

confidence: 99%

Antitumor and Anti-Metastatic Effects of Citral-Loaded Nanostructured Lipid Carrier in 4T1-Induced Breast Cancer Mouse Model

et al. 2020

Self Cite

View full text Add to dashboard Cite

Cancer nano-therapy has been progressing rapidly with the introduction of many novel drug delivery systems. The previous study has reported on the in vitro cytotoxicity of citral-loaded nanostructured lipid carrier (NLC-Citral) on MDA-MB-231 cells and some preliminary in vivo antitumor effects on 4T1 breast cancer cells challenged mice. However, the in vivo apoptosis induction and anti-metastatic effects of NLC-Citral have yet to be reported. In this study, the in vitro cytotoxic, anti-migration, and anti-invasion effects of NLC-Citral were tested on 4T1 breast cancer cells. In addition, the in vivo antitumor effects of oral delivery of NLC-Citral was also evaluated on BALB/c mice induced with 4T1 cells. In vitro cytotoxicity results showed that NLC-Citral and citral gave similar IC50 values on 4T1 cells. However, wound healing, migration, and invasion assays reflected better in vitro anti-metastasis potential for NLC-Citral than citral alone. Results from the in vivo study indicated that both NLC-Citral and citral have anti-tumor and anti-metastasis effects, whereby the NLC-Citral showed better efficacy than citral in all experiments. Also, the delay of tumor progression was through the suppression of the c-myc gene expression and induction of apoptosis in the tumor. In addition, the inhibition of metastasis of 4T1 cells to lung and bone marrow by the NLC-Citral and citral treatments was correlated with the downregulation of metastasis-related genes expression including MMP-9, ICAM, iNOS, and NF-kB and the angiogenesis-related proteins including G-CSF alpha, Eotaxin, bFGF, VEGF, IL-1alpha, and M-CSF in the tumor. Moreover, NLC-Citral showed greater downregulation of MMP-9, iNOS, ICAM, Eotaxin, bFGF, VEGF, and M-CSF than citral treatment in the 4T1-challenged mice, which may contribute to the better anti-metastatic effect of the encapsulated citral. This study suggests that NLC is a potential and effective delivery system for citral to target triple-negative breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Antitumor and Anti-Metastatic Effects of Citral-Loaded Nanostructured Lipid Carrier in 4T1-Induced Breast Cancer Mouse Model

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other studies have shown that citral is a is a key component of the essential oils extracted from lemon balm with antiproliferative effect in several leukemia cell lines (P388, NB4, MOLT-4) via the induction of apoptosis (Xia et al, 2013). Recent study demonstrated that citral nanostructured lipid carrier inhibited the proliferation of breast cancer cells in vitro (MDA MBA-231 human breast cancer cells), majorly through the induction of apoptosis, anti-metastasis, anti-angiogenesis potentials, and reducing the tumor weight and size without altering the therapeutic effects of citral (Nordin et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

In vitro antiproliferative activity of Melissa officinalis L (Lamiaceae) leaves essential oil

Nikšić¹,

Durić²,

Sijamic³

et al. 2019

Bol Latinoam Caribe Plant Med Aromat

View full text Add to dashboard Cite

In the present study, we investigated the antiproliferative activity of essential oil from leaves of Melissa officinalis L. grown in Southern Bosnia and Herzegovina. In vitro evaluation of antiproliferative activity of the M. officinalis essential oil was carried out on three human tumor cell lines: MCF-7, NCI-H460 and MOLT-4 by MTT assay. M. officinalis essential oil was characterized by high percentage of monoterpenes (77,5%), followed by the sesquiterpene fraction (14,5%) and aliphatic compounds (2,2%). The main constituents of the essential oil of M. officinalis are citral (47,2%), caryophyllene oxide (10,2%), citronellal (5,4%), geraniol (6,6%), geranyl acetate (4,1%) and βcaryophyllene (3,8%). The essential oil showed significant antiproliferative activity against three cancer cell lines, MOLT-4, MCF-7, and NCI-H460 cells, with GI50 values of <5, 6±2 and 31±17 µg/mL, respectively. The results revealed that M. officinalis L. essential oil has a potential as anticancer therapeutic agent.Resumen: En el presente estudio, investigamos la actividad antiproliferativa del aceite esencial de las hojas de Melissa officinalis L. cultivadas en el sur de Bosnia y Herzegovina. La evaluación in vitro de la actividad antiproliferativa del aceite esencial de M. officinalis se llevó a cabo en tres líneas celulares de tumores humanos: MCF-7, NCI-H460 y MOLT-4 utilizando el ensayo de MTT. El aceite esencial de M. officinalis se caracterizó por un alto porcentaje de monoterpenos (77,5%), seguido de la fracción sesquiterpénica (14,5%) y compuestos alifáticos (2,2%). Los principales constituyentes del aceite esencial de M. officinalis fueron citral (47,2%), óxido de cariofileno (10,2%), citronelal (5,4%), geraniol (6,6%), acetato de geranilo (4, 1%), y β-cariofileno (3,8%). El aceite esencial mostró una actividad antiproliferativa significativa contra las líneas celulares de cáncer MOLT-4, MCF-7 y NCI-H460, con valores GI50 de <5, 6±2 y 31±17 µg/mL, respectivamente. Los resultados revelaron que el aceite esencial de M. officinalis L. tiene potencial como agente terapéutico contra el cáncer.Palabras clave: Melissa officinalis L.; Aceite esencial; Agentes antiproliferativos; MOLT-4; MCF-7; NCI-H460 Recibido |

show abstract

“…Beyond, citral attracted scientists' attention towards its anticancer properties in a variety of cancer types, such as melanoma [259], colon cancer [260], and breast cancer [261]. Bayala and co-authors provided evidence about Cymbopogon citratus and Cymbopogon gigantescus essential oil cytotoxic activity, which have citral as its major component and significantly decreased prostate and glioblastoma cancer cell survival [262].…”

Section: Citralmentioning

confidence: 99%

“…Initially, they showed that NLC as a drug delivery system for citral has the potential to sustain drug release without inducing any toxicity [269]. Then, they showed that NLC-citral regulated apoptosis, cell cycle, and metastasis signaling, all key signaling pathways related to cancer development [261]. In addition, citral was pointed as a potential effective additive to chemotherapeutic treatment [270,271].…”

Section: Citralmentioning

confidence: 99%

Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant

et al. 2020

View full text Add to dashboard Cite

Medicinal use of Cannabis sativa L. has an extensive history and it was essential in the discovery of phytocannabinoids, including the Cannabis major psychoactive compound—Δ9-tetrahydrocannabinol (Δ9-THC)—as well as the G-protein-coupled cannabinoid receptors (CBR), named cannabinoid receptor type-1 (CB1R) and cannabinoid receptor type-2 (CB2R), both part of the now known endocannabinoid system (ECS). Cannabinoids is a vast term that defines several compounds that have been characterized in three categories: (i) endogenous, (ii) synthetic, and (iii) phytocannabinoids, and are able to modulate the CBR and ECS. Particularly, phytocannabinoids are natural terpenoids or phenolic compounds derived from Cannabis sativa. However, these terpenoids and phenolic compounds can also be derived from other plants (non-cannabinoids) and still induce cannabinoid-like properties. Cannabimimetic ligands, beyond the Cannabis plant, can act as CBR agonists or antagonists, or ECS enzyme inhibitors, besides being able of playing a role in immune-mediated inflammatory and infectious diseases, neuroinflammatory, neurological, and neurodegenerative diseases, as well as in cancer, and autoimmunity by itself. In this review, we summarize and critically highlight past, present, and future progress on the understanding of the role of cannabinoid-like molecules, mainly terpenes, as prospective therapeutics for different pathological conditions.

show abstract

In vitro cytotoxicity and anticancer effects of citral nanostructured lipid carrier on MDA MBA-231 human breast cancer cells

Cited by 79 publications

References 77 publications

Antitumor and Anti-Metastatic Effects of Citral-Loaded Nanostructured Lipid Carrier in 4T1-Induced Breast Cancer Mouse Model

Antitumor and Anti-Metastatic Effects of Citral-Loaded Nanostructured Lipid Carrier in 4T1-Induced Breast Cancer Mouse Model

In vitro antiproliferative activity of Melissa officinalis L (Lamiaceae) leaves essential oil

Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant

Contact Info

Product

Resources

About